New 5-Year Data Demonstrates Long-Term Efficacy and Safety of Deuterated Colexitinib in Plaque Psoriasis

According to a press release, Bristol Myers Squibb (Bristol Myers Squibb) recently released its new drug Deucravacitinib (Deucravacitinib) in the treatment of moderate to severe plaque psoriasis5-year results. The data come from a long-term trial designed to evaluate the drug's efficacy and safety in adult patients. Deuterated colexitinib is a selective tyrosine kinase 2 inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in September 2022 and is in a long-term extension trial called POETYK PSO.

These5-year study results continue to support the safety and efficacy of colexitinib in adults with moderate to severe plaque psoriasis who continue taking the drug for 5 years. The importance of this study lies not only in the long-term data it provides, but also in how these data further confirm the value of deuterated colexitinib in the field of dermatology treatment.

According to the study results, among 513 patients who received continuous deuterated colexitinib treatment, up to 72.1% of patients achieved PASI 75 (i.e., a 75% reduction in psoriasis area and severity index) at year 1, and this proportion remained at 67.3% at year 5. This data demonstrates that colexitinib can effectively control psoriasis symptoms and help patients achieve a higher degree of skin improvement with long-term use.

In addition, the study also showed that45.9% of patients achieved PASI 90 (ie, the psoriasis area and severity index was reduced by 90%) after 1 year, and at 5 years, 46.3% of patients still maintained this treatment effect. These data demonstrate the sustained efficacy of deuterated colexitinib in long-term treatment, reflecting its potential in psoriasis management.

In terms of patient overall condition assessment, more than half of the patients achieved an overall assessment of 0/1 at 1 year (57.5%) and 5 years (52.6%), which means that the condition of these patients has been significantly controlled and improved. These durability results provide clinicians with important information when treating patients with psoriasis, allowing them to better evaluate the effectiveness of deuterated colexitinib as a treatment option.

In terms of security, the press release noted that based on the reviewSafety analysis of 1,519 patients did not show any new safety signals for deuterated colexitinib. Safety signals such as the incidence of serious infections, major cardiovascular adverse events and malignancies were very low and did not increase over time. This data demonstrates that deuterated colexitinib has a favorable safety profile during long-term treatment, consistent with real-world data from other immunomodulators.

The cumulative number of patient-years of exposure in this study reached 5,000, further demonstrating that deuterated colexitinib is safe as a long-term treatment option for patients with moderate to severe plaque psoriasis. This will provide an important basis for clinical practice and promote deuterated colexitinib to become the drug of choice for more patients with psoriasis.

Overall, deuterated colexitinib shows good potential in creating a new standard of care for psoriasis. With the in-depth understanding of deuterated colexitinib and the continuous updating of long-term efficacy and safety data, we have reason to believe that this new drug will play a greater role in the field of psoriasis treatment and help more patients improve their quality of life.

References:https://www.healio.com/news/dermatology/20250303/new-5year-data-showcase-sotyktus-longterm-efficacy-safety-for-plaque-psoriasis